By blocking SGLT-2, a reduced PDA risk was found in SGLT-2 inhibitor users, and a decreased cancer proliferation in preclinical pancreatic cancer models when treated with SGLT-2 inhibitor (Dicembrini et al., 2019; Dąbrowski, 2021). Here, SLC5A2 is linked to cancer.